Inhibrx, Inc. Balance Sheet | Understand Stock

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020
Assets
Current assets:
Cash and cash equivalents
Accounts receivable
Nonrelated Party
Related Party
Total accounts receivable
Receivables from related parties
Other receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating right-of-use asset
Other non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued expenses
Deferred revenue
Current portion of long-term debt, net of discount
Current portion of operating lease liability
Paycheck Protection Program loan
Other current liabilities
Total current liabilities

Convertible notes, net of discount
Derivative liabilities
Long-term debt, including final payment fee
Long-term debt, including debt discount and final payment fee
Non-current portion of operating lease liability
Non-current portion of deferred revenue
Other non-current liabilities
Total liabilities
Convertible preferred stock, $0.0001 par value; no shares authorized or outstanding at December 31, 2020; 25,765,000 shares authorized at December 31, 2019; 12,534,331 shares issued and outstanding at December 31, 2019; liquidation preferences of $87.5 million at December 31, 2019.
Stockholders’ equity
Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023.
Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 49,234,225 and 47,369,511 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.
Additional paid-in-capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments